机译:确定疟原虫蛋白酶体抑制剂特异性的决定因素
Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA;
Columbia Univ, Dept Microbiol & Immunol, Med Ctr, New York, NY 10032 USA;
Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA;
Columbia Univ, Dept Microbiol & Immunol, Med Ctr, New York, NY 10032 USA;
Columbia Univ, Dept Microbiol & Immunol, Med Ctr, New York, NY 10032 USA;
Univ Cape Town, Drug Discovery & Dev Ctr H3D, ZA-7701 Rondebosch, South Africa;
Univ Cape Town, Drug Discovery & Dev Ctr H3D, ZA-7701 Rondebosch, South Africa;
Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA;
Univ Cape Town, Drug Discovery & Dev Ctr H3D, ZA-7701 Rondebosch, South Africa;
Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA;
Columbia Univ, Dept Microbiol & Immunol, Med Ctr, New York, NY 10032 USA;
Columbia Univ, Dept Microbiol & Immunol, Med Ctr, New York, NY 10032 USA;
Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA;
机译:使用具有寄生虫特异性毒性的环氧酮抑制剂验证蛋白酶体作为疟原虫中的治疗靶标
机译:由单克隆抗体定义的间日疟原虫和卵形疟原虫的阶段特异性和物种特异性抗原。
机译:由单克隆抗体定义的间日疟原虫和卵形疟原虫的阶段特异性和物种特异性抗原。
机译:二氢哌塞米菌素抑制硅片在硅中的疟原虫蛋白质蛋白酶体系
机译:高通量筛网识别疟原虫蛋白酶的特异性抑制剂,PFCLPP
机译:定义特异性的决定因素疟原虫蛋白酶体抑制剂
机译:使用具有寄生虫特异性毒性的环氧酮抑制剂验证蛋白酶体作为疟原虫治疗靶标的作用